Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.
MBZUAI's Kun Zhang is applying causal machine learning to improve drug development and precision medicine, focusing on answering 'why' questions. Traditional drug development is costly (est. $2B) due to extensive studies needed to determine drug toxicity and efficacy. Zhang is combining causal ML with organs-on-chips technology to improve pre-clinical drug testing, aiming to reduce the failure rate of drugs in human trials. Why it matters: By improving the accuracy of pre-clinical drug testing, this research could significantly reduce the cost and time required to bring new medicines to market in the region and worldwide.
KAUST researchers have developed deepBlastoid, a deep learning tool for evaluating models of human embryo development, called blastoids. deepBlastoid can evaluate images of blastoids at speeds 1000 times faster than expert scientists, processing 273 images per second. Trained on over 2000 microscopic blastoid images, it assesses the impact of chemicals on blastoid development using over 10,000 images. Why it matters: This AI tool accelerates research into early pregnancy, fertility complications, and the impact of chemicals on embryo development, with implications for reproductive technologies.
MBZUAI researchers have developed MorphDiff, a diffusion model that predicts cell morphology from gene expression data. MorphDiff uses the transcriptome to generate realistic post-perturbation images, either from scratch or by transforming a control image. The model combines a Morphology Variational Autoencoder (MVAE) with a Latent Diffusion Model, enabling both gene-to-image generation and image-to-image transformation. Why it matters: This could significantly accelerate drug discovery and biological research by allowing scientists to preview cellular changes before conducting experiments.